EYPT Earnings

EYPT reported its earnings on 2026-03-04, showcasing a revenue of 620.00K against an estimate of 540.00K, resulting in a 14.81% surprise. The EPS was -0.81, surpassing the expected -0.78 by -3.85%. The stock experienced a -1.75% price change on the earnings day and a -14.47% change over the next five days, reflecting market reactions to the results.

Following EYPT's earnings announcement on 2026-03-04, the stock price moved by -1.75% on the day of the release. Over the subsequent five days, it saw a -14.47% change. Historically, EYPT's stock price tends to shift by an average of 0.63% in the 10 days leading up to earnings and -1.25% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate EYPT's annual revenue to reach 400.00K, while the EPS is projected at -0.67. These estimates reflect recent revisions, with revenue estimates revised upward by 0.11% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between EYPT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 0.11%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EYPT's stock price typically moves by 0.63% in the 10 days before its earnings and -1.25% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.67 and revenue of 400.00K.

The earnings call highlights strong financial stability, with cash funding operations into Q4 2027, and promising developments in the DURAVYU trials, targeting a $10 billion market. The Q&A reveals positive sentiment about DURAVYU's multi-mechanism profile and commercial readiness, despite some unclear responses. The company's strategic positioning and promising trial outcomes suggest a positive stock price reaction, although the lack of a market cap limits the prediction's precision.